Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance his Department provides to NHS bodies regarding engagement with external academic publications that discuss practices which are illegal under UK law.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, regulated healthcare professionals are required by law to maintain standards in competence, ethics, patient safety, and accountability. Failure to meet these standards can result in investigation, restrictions, suspension, or permanent removal from the register. Responsible employment practices are an important element in ensuring all those working in the research and innovation system can thrive and deliver high quality research.
Researchers funded through UK Research and Innovation (UKRI), National Institute for Health and Care Research (NIHR), and other publicly funded sources are expected to comply with the highest standards of research ethics and integrity, including responsible publication practices. Both UKRI and NIHR are signatories to the Concordat to Support Research Integrity.
The NIHR's support for the San Francisco Declaration on Research Assessment aligns with its dedication to research integrity, transparency, and fostering a culture where research excellence is measured in a more holistic and meaningful way.
Asked by: Andrew Lewin (Labour - Welwyn Hatfield)
Question to the Department for Education:
To ask the Secretary of State for Education, what whether she has considered screening all primary school age children for colour blindness.
Answered by Georgia Gould - Minister of State (Education)
The department knows that effective early identification and intervention is critical in improving the outcomes of children and young people with special educational needs and disabilities (SEND).
Whilst the department does not have any current plans to introduce screening for all primary school age children for colour blindness, to support settings to identify need early, we are strengthening the evidence base of what works to improve early identification in mainstream settings. Recently published evidence reviews from University College London will help to drive inclusive practices. They highlight what the best available evidence suggests are the most effective tools, strategies and approaches for teachers and other relevant staff in mainstream settings to identify and support children and young people with different types of needs.
We also recently announced new government-backed research into SEN identification, which will be delivered by UK Research Innovation (UKRI) in partnership with the department. This will aim to develop and test trusted and effective approaches to help the early identification of children needing tailored educational support.
Asked by: Bobby Dean (Liberal Democrat - Carshalton and Wallington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with UKRI and the National Institute for Health and Care Research on supporting new and emerging treatments for low‑grade gliomas.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR).
Government responsibility for delivering cancer research is shared between Department for Health and Social Care, with research delivered by the NIHR, and Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.
Department of Health and Social Care and Department of Science, Innovation and Technology officials meet regularly to discuss a range of research investments to drive the maximum collective research impact on policy, practice, and individual lives.
The NIHR is continuing to invest in brain tumour research. In December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million in the consortium, with significant further funding due to be awarded early in 2026. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.
The NIHR continues to welcome high quality funding applications for research into any aspect of human health and care, including low-grade glioma.
Asked by: Dan Norris (Independent - North East Somerset and Hanham)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to support AI development in the West of England.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Government is putting artificial intelligence at the heart of our mission to grow the UK economy. We are backing British researchers and firms and catalysing regional AI clusters so communities across the country, including in the West of England, can benefit.
We are opening a £250m procurement for the next phase of the AI Research Resource, our publicly owned supercomputers which can be used – for free – by UK researchers and business. One of the supercomputers, Isambard-AI, is based in Bristol and is one of the world’s top 10 public supercomputers and the 4th greenest.
The Government will act as a “first customer” for promising UK AI hardware through an advance market commitment of up to £100 million, giving UK companies the opportunity to grow and compete. We are also backing British scale‑ups via a new Sovereign AI Unit, supported by around £500 million, and driving local productivity through targeted skills and business adoption programmes that help SMEs adopt AI and equip workers with essential AI skills.
Together, these measures will place communities such as in the West of England in a strong position to seize the opportunities presented by AI.
Asked by: Julian Smith (Conservative - Skipton and Ripon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2025 to Question 36392, if he will provide an update on funding for lobular breast cancer research.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises the crucial need for research into all forms of cancer, including lobular breast cancer. We remain committed to the role of research in driving a stronger collective understanding of the biology behind lobular breast cancer and to improve outcomes for women.
Government responsibility for delivering cancer research is shared between Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation, which includes the Medical Research Council.
In November 2025, the NIHR issued a highlight notice encouraging applications for new research into lobular breast cancer, to improve the detection, diagnosis, treatment, and long-term surveillance of patients.
The NIHR continues to welcome high quality funding applications for research into any aspect of human health and care, including lobular breast cancer.
Asked by: Rachel Gilmour (Liberal Democrat - Tiverton and Minehead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress his Department has made on implementing the Dame Barbara Windsor Dementia Goals programme.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Dame Barbara Windsor Dementia Goals programme, with up to £150 million expected to be allocated to, or aligned with it, aims to speed up the development of new treatments for dementia and neurodegenerative conditions by accelerating innovations in biomarkers, clinical trials, and implementation. This is co-chaired by Hilary Evans-Newton CBE and Professor Nadeem Sarwar.
So far, the programme has invested approximately £100 million into biomarker innovation projects, experimental medicine studies, and clinical trial infrastructure. This covers a broad range of biomarker technologies and studies to help researchers, patients, and industry partners work together to better understand how dementia begins and progresses. This amount also supports the Medical Research Council’s Dementia Trials Accelerator which aims to embed more innovation in how clinical trials are designed and delivered in order to increase the speed and quality, while driving down the cost of large-scale trials, as well as the National Institute for Health and Care Research’s UK Dementia Trials Network which seeks to speed up early-stage clinical trials.
The programme is now setting up the Neurodegeneration Initiative, which will be a globally unique, not-for-profit, industry led, public-private partnership with charitable status, that will work together across the Government, industry, academia, the National Health Service, and third sector, and will deliver the programme’s remaining objectives.
Asked by: Joshua Reynolds (Liberal Democrat - Maidenhead)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what estimate she has made of the cost of cyber attacks to the economy in 2025.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
In November 2025, the government published a set of independent research reports quantifying the impact of cyber attacks on the UK economy. These reports demonstrate the scale of the potential cost of cyber attacks to UK businesses, with KPMG’s report Economic Modelling of Sector Specific Costings of Cyber Attacks estimating the average cost of a significant cyber attack for an individual business in the UK to be almost £195,000. Scaled to an annual UK cost to businesses, this amounts to an estimated £14.7 billion.
The Government has developed tools for businesses to protect themselves, including:
The Government is also taking further action to protect the economy. The Cyber Security and Resilience Bill will boost our cyber defences and better protect our essential services. This year, we will publish a new National Cyber Action Plan setting out how Government will respond to the cyber threat and work with industry to raise resilience across the economy.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to help ensure that UK universities remain competitive in attracting global research talent.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
To keep our world-leading universities globally competitive, the Post-16 Education and Skills White Paper sets out a joint DfE–DSIT vision for a financially sustainable higher education sector that delivers better value for students, supports local growth, and meets labour market needs. This includes record DSIT R&D investment of £58.5 billion between 2026/27 and 2029/30.
The UK’s immigration offer attracts research talent through visa routes such as the fast-track Global Talent visa, complemented by funding via UKRI and National Academies fellowships and professorships, our association to Horizon Europe, and the Global Talent Fund to retain world-class researchers.
UKRI allows visa costs, including the Immigration Health Surcharge, to be claimed on grants, and many other organisations also allow these costs on their grants. Visa costs are also allowable costs for researchers on Horizon Europe grants.
Asked by: Tom Tugendhat (Conservative - Tonbridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the reasons people with brain cancer are seeking treatment outside the UK, particularly in Germany, including the trend in the level of such treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Ensuring patients have access to the latest and most effective treatment options is a top priority for the Government.
That is why we are committed to supporting an innovative clinical research ecosystem in the United Kingdom so that patients in this country can be among the first to benefit as we make the National Health Service fit for the future.
The Government is supportive of Scott Arthur’s Private Members Bill on rare cancers, which will make it easier for clinical trials into rare cancers, such as brain cancers, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government, with regard to the independent report Chief Medical Officer’s annual report 2025: infections, published on 4 December 2025, what action they plan to take in response to the specific additional recommendation about the link between agricultural use of novel fungicides and the spread of resistant strains of fungi with the capacity to cause serious disease.
Answered by Baroness Hayman of Ullock - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
This Government recognises the importance of carefully managing pesticide use, including fungicides, to protect the environment and human health and address the risks of resistance.
During the plant protection product approvals process, the Health and Safety Executive considers the potential for resistance development in the target pest organism. Where resistance is known or anticipated, limitations are placed on product use to mitigate resistance developing. Defra is also funding work by the Agriculture and Horticulture Development Board which provides farmers best practice to minimise the risk of resistance emerging.
Through the National Institute for Health and Care Research, the Department of Health and Social Care has provided over £12 million in funding over the last five years for research into fungal infections and tackling antifungal resistance. Defra has also co-funded a research programme for UK Research and Innovation on ‘Transdisciplinary research to tackle antimicrobial resistance’.
The UK Health Security Agency (UKHSA) is routinely monitoring threats from antifungal resistance. The National Mycology Reference Laboratory performs antifungal susceptibility testing of fungi from human infections from across the UK. UKHSA also monitors antifungal susceptibility testing data for fungal yeast pathogens isolated from blood samples from local microbiology laboratories in England. Trends are published annually.